A-Alpha Bio will receive $14.5 million from the Department of Defense (DOD) to expand a project with a national lab to help prepare for future biological threats using the company’s machine learning ...

The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Yatiri Bio Inc. today announced it has received a grant from the Gates Foundation to launch a one-year project, Proteomics Interoperability, aimed at ...

The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc.

Chemists from Ed Tate’s laboratory at Imperial College London have launched a company, Siftr Bio, that aims to improve the chemistry used to link antibodies to cancer-killing molecules in therapies ...

Today, we take a look at clinical-stage biopharma firm Gossamer Bio, whose stock is up some 175% so far in 2025. Seralutinib, Gossamer's lead asset, is advancing to late-stage development and has ...

- Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portfolio - ...

Bio-Rad stock looks undervalued, boosted by its Sartorius stake, but headwinds and volatile guidance cap upside. Click here ...

Cabaletta Bio, Inc. has announced its participation in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 11:05 a.m. ET in New York City. The biotechnology company, ...

Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ: SNY). The new agreement is built on the existing relationship between the two ...